7675 The Effects of Fibroblast Growth Factor-21 Analogues in Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Bibliographic record
Abstract
Abstract Disclosure: J.C. Cardoso: None. R.Y. Ura Sudo: None. M.C. Souza: None. F.D. Pessôa: None. F.A. Moraes: None. N.M. Oliveira: None. F.A. Kelly: None. L.M. Lopes: None. P.G. Lima: None. M.S. Barros: None. F.F. Bandeira: None. Fibroblast growth factor 21 (FGF-21), a potent insulin sensitizer, has been shown to improve lipid profile, glucose metabolism and energy expenditure. The FGF-21 analogues emerged as a promising treatment avenue for critical components of metabolic syndrome, such as metabolic dysfunction associated steatohepatitis, hypertriglyceridemia, diabetes, and obesity. However, their potential treatment effects remain unclear. We systematically searched Pubmed, Web of Science, and Cochrane databases, from inception to January 2024, for randomized controlled trials (RCT) comparing the effects of FGF-21 analogues on glycemic control and lipid profile against placebo. Statistical analysis was performed in R software 4.3.1. A random-effects model was employed to compute mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI) for continuous and binary endpoints, respectively. A p-value of < 0.05 was considered statistically significant. Heterogeneity was examined with the Cochran Q test, prediction interval and I² statistics. The results were reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement guideline. The protocol was prospectively registered in PROSPERO under CRD42023493083 identification number. A total of 15 RCTs with 1427 patients were included, of whom 1038 (72.7%) were randomized to FGF-21 analogues therapy. The mean age was 55 years and the mean body mass index (Kg/m^2) was 35.2. Over a mean follow-up time of 20.8 weeks, the FGF-21 group presented a significant decrease in body weight (MD -0.75%; 95% CI -1.25 to -0.24; p=0.004; I²=0%), serum trigliceryde (MD -22.76%; 95% CI -30.48 to -15.04; p<0.001; I²=62%), LDL-C (MD -5.46%; 95% CI -9.73 to -1.19; p=0.012; I²=33%), nonHDL-C (MD -10.65%; 95% CI -14.13 to -7.17; p<0.001; I²=0%) and a significant increase in HDL-C (MD 10.50%; 95% CI 6.70 to 14.30; p<0.001; I²=67%) and adiponectin (MD 18.80%; 95% CI 10.26 to 27.33; p<0.001; I²=88%). Despite these favorable outcomes over placebo, the FGF-21 analogues caused nonsignificant decreases in HOMA-IR (MD -1.38; 95% CI -4.69 to 1.92; p=0.412; I²=85%), HbA1c (MD -0.52%; 95% CI -1.45 to 0.41; p=0.275; I²=99%), plasma glucose (MD -0.45 mg/dL; 95% CI -3.99 to 3.08; P = 0.802; I²=15%), plasma insulin (MD -7.24%; 95% CI -19.16 to 4.68; p=0.234; I²=0%), C peptide (MD -0.37 nmol/L; 95% CI -0.86 to 0.10; P = 0.126; I²=78%) and apolipoprotein B (MD -2.36%; 95% CI -26.45 to 21.72; p=0.848, I²=93%). In conclusion, the use of FGF-21 analogues led to significant improvements in the lipid profile without changes in glycemic control. Presentation: 6/3/2024
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.007 | 0.010 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.030 | 0.022 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; both teacher heads agree on what is shown here.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".